全文获取类型
收费全文 | 2595篇 |
免费 | 117篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 22篇 |
儿科学 | 470篇 |
妇产科学 | 44篇 |
基础医学 | 234篇 |
口腔科学 | 26篇 |
临床医学 | 171篇 |
内科学 | 504篇 |
皮肤病学 | 58篇 |
神经病学 | 129篇 |
特种医学 | 72篇 |
外科学 | 479篇 |
综合类 | 55篇 |
预防医学 | 80篇 |
眼科学 | 51篇 |
药学 | 151篇 |
中国医学 | 6篇 |
肿瘤学 | 170篇 |
出版年
2023年 | 16篇 |
2022年 | 11篇 |
2021年 | 48篇 |
2020年 | 29篇 |
2019年 | 42篇 |
2018年 | 82篇 |
2017年 | 33篇 |
2016年 | 71篇 |
2015年 | 50篇 |
2014年 | 85篇 |
2013年 | 107篇 |
2012年 | 190篇 |
2011年 | 169篇 |
2010年 | 119篇 |
2009年 | 71篇 |
2008年 | 133篇 |
2007年 | 134篇 |
2006年 | 115篇 |
2005年 | 108篇 |
2004年 | 84篇 |
2003年 | 104篇 |
2002年 | 97篇 |
2001年 | 82篇 |
2000年 | 78篇 |
1999年 | 62篇 |
1998年 | 26篇 |
1997年 | 15篇 |
1996年 | 19篇 |
1995年 | 15篇 |
1994年 | 21篇 |
1993年 | 9篇 |
1992年 | 48篇 |
1991年 | 51篇 |
1990年 | 32篇 |
1989年 | 29篇 |
1988年 | 26篇 |
1987年 | 28篇 |
1986年 | 28篇 |
1985年 | 30篇 |
1984年 | 19篇 |
1983年 | 13篇 |
1981年 | 21篇 |
1979年 | 15篇 |
1978年 | 16篇 |
1977年 | 25篇 |
1976年 | 26篇 |
1975年 | 10篇 |
1974年 | 11篇 |
1973年 | 8篇 |
1968年 | 8篇 |
排序方式: 共有2722条查询结果,搜索用时 15 毫秒
1.
2.
3.
Rimesh Pal Naresh Sachdeva Soham Mukherjee Vikas Suri Deepy Zohmangaihi Sant Ram Goverdhan Dutt Puri Ashish Bhalla Shiv Lal Soni Navin Pandey Anil Bhansali Sanjay Kumar Bhadada 《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2021,15(1):193-196
Background and aimsPatients with diabetes mellitus (DM) often demonstrate impaired antibody response to influenza/hepatitis B vaccines. Hence, we compared anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with and without type 2 diabetes mellitus (T2DM).MethodsRecords of non-severe COVID-19 patients admitted at our institution between April 10, 2020 and May 20, 2020 were retrieved. Qualitative detection of total (IgG + IgM) anti-SARS-CoV-2 antibody was performed using electrochemiluminescence immunoassay in plasma samples collected at least 14 days post-polymerase chain reaction (PCR) confirmation of diagnosis.ResultsThirty-one non-severe COVID-19 patients were included. Nine patients (29%) had T2DM with mean HbA1c at admission of 8.3 ± 1.0%. Anti-SARS-CoV-2 antibody was estimated at a median of 16 (14–17) days post-PCR confirmation of COVID-19 diagnosis. Only three patients (10%) were seronegative, and all had T2DM. Patients with T2DM were more likely to have non-detectable anti-SARS-CoV-2 antibodies than those without DM (p = 0.019).ConclusionsCOVID-19 patients with T2DM may not undergo seroconversion even after two weeks of diagnosis. Impaired seroconversion could theoretically increase the risk of reinfections in patients with DM. However, the finding requires validation in large-scale studies involving serial estimations of anti-SARS-CoV-2 antibodies in patients with and without DM. 相似文献
4.
5.
A.L. Kühn S.R. Satti T. Eden K. de Macedo Rodrigues J. Singh F. Massari M.J. Gounis A.S Puri 《AJNR. American journal of neuroradiology》2021,42(3):487
BACKGROUND AND PURPOSE:Transradial access for neurointerventional procedures has been proved a safer and more comfortable alternative to femoral artery access. We present our experience with transradial (distal radial/anatomic snuffbox and radial artery) access for treatment of intracranial aneurysms using all 3 FDA-approved flow diverters.MATERIALS AND METHODS:This was a high-volume, dual-center, retrospective analysis of each institution’s data base between June 2018 and June 2020 and a collection of all patients treated with flow diversion via transradial access. Patient demographic information and procedural and radiographic data were obtained.RESULTS:Seventy-four patients were identified (64 female patients) with a mean age of 57.5 years with a total of 86 aneurysms. Most aneurysms were located in the anterior circulation (93%) and within the intracranial ICA (67.4%). The mean aneurysm size was 5.5 mm. Flow diverters placed included the Pipeline Embolization Device (Flex) (PED, n = 65), the Surpass Streamline Flow Diverter (n = 8), and the Flow-Redirection Endoluminal Device (FRED, n = 1). Transradial access was successful in all cases, but femoral crossover was required in 3 cases (4.1%) due to tortuous anatomy and inadequate support of the catheters in 2 cases and an inability to navigate to the target vessel in a patient with an aberrant right subclavian artery. All 71 other interventions were successfully performed via the transradial approach (95.9%). No access site complications were encountered. Asymptomatic radial artery occlusion was encountered in 1 case (3.7%).CONCLUSIONS:Flow diverters can be successfully placed via the transradial approach with high technical success, low access site complications, and a low femoral crossover rate.The transradial access (TRA), including distal radial artery (dRA) access in the anatomic snuffbox and radial artery (RA) access at the palmar surface of the wrist, is being increasingly used as primary vascular access for neurointerventional procedures. In prior years, large randomized trials in the field of interventional cardiology and more recent articles in neurointerventional surgery have shown higher patient preference for the TRA, cost reduction, as well as lower morbidity and mortality compared with the traditional transfemoral access (TFA).1-11 Reduction in access site complications has been a particular advantage of wrist over femoral access and is an important consideration for vascular access choice in the treatment of intracranial aneurysms using flow diversion. Patients undergoing flow diversion are required to take dual-antiplatelet agents and receive heparin during the procedure, all of which increase the risk of bleeding from the access site.12 Also, flow diverters (FDs) may require large-bore catheter assemblies for delivery and deployment, which may increase the risk of radial artery occlusion, access site bleeding, or vascular injury.13,14To date, only a limited number of case reports and case series have described the safety and feasibility of TRA for the treatment of intracranial aneurysms using flow diverters.15-22Recently, a large, retrospective multicenter study reported the safety of TRA for flow diversion, showing a lower access site (P = .039) and overall complication rate (P = .035).12 This study, however, did not cover catheter systems, patient functional outcome, and aneurysm occlusion. Here, we report our experience with TRA (dRA [anatomic snuffbox] and RA) for the treatment of intracranial aneurysms using all 3 FDA-approved flow diverters, including technical feasibility, procedural safety, patient outcome, and aneurysm occlusion on follow-up. Additionally, we reviewed the current literature on use of flow diverters via TRA. 相似文献
6.
7.
Suyash S. Kulkarni Nitin Sudhakar Shetty Kunal B. Gala Mohd Shariq Ashish Gulia Ashwin M. Polnaya Neeraj G. Shetty Amit Kumar Janu Amitkumar Choudhari Ajay Puri 《Journal of vascular and interventional radiology : JVIR》2021,32(4):504-509
PurposeTo evaluate safety and long-term efficacy of radiofrequency (RF) ablation in treatment of chondroblastoma.Materials and MethodsThis retrospective analysis comprised 27 consecutive patients with histopathologically proven chondroblastoma treated by RF ablation. The tumors were located in the proximal humerus (n = 6), proximal tibia (n = 8), proximal femur (n = 6), distal femur (n = 5), acromion process (n = 1), and lunate (n = 1). In 19 patients (70.3%), the tumor was in the weight-bearing area of the bone. Clinical response was assessed by comparing pain scores and functional assessment by Musculoskeletal Tumor Society (MSTS) score before and after ablation. Patients were followed for a minimum of 1 year to rule out complications and recurrence.ResultsTechnical success rate was 100%. Mean pain score before the procedure was 7.34 (range, 7–9); all patients experienced a reduction in pain, with 25 (92.6%) patients reporting complete pain relief at 6 weeks. Mean MSTS score before the procedure was 15.4, whereas mean MSTS score at 6 weeks after the procedure was 28.6, suggesting significant functional improvement (P < .0001). Two patients developed osteonecrosis and collapse of the treated bone. There were no recurrences.ConclusionsPercutaneous RF ablation is a safe and effective option for treating chondroblastoma of the appendicular skeleton. 相似文献
8.
9.
10.